'Calcineurin inhibitors' presentation slideshows

Immunoauppresive Drugs for Renal Transplantation

For most patients with chronic kidney failure, kidney transplantation has the greatest potential for restoring a healthy and productive life. The risk of acute rejection is the highest in the first months after transplantation induction phase and diminishes afterwards maintenance phase . Immunosuppression should be at the highest level in the early period and reduced for long term therapy. At present, conventional immunosuppressive protocols consist of the triple therapy a calcineurin inhibitor, an adjunctive agent, corticosteroids. The development of new immunosuppressives drugs is aimed not only at improving short term outcomes, but also achieving better safety, less nephrotoxicity and minimal side effects. Suppression of allograft rejection is the central issue in renal transplantation RT . Thus, development of immunosuppressive agents is the key for successful allograft function. Immunosuppression agents in RT have evolved over the last six decades beginning with total lymphoid irradiation to the currently available immunosuppressive strategies, which have significantly reduced the incidence of acute rejection episodes and improved short term graft and patient outcomes. However their use is associated with long term graft dysfunction, hypertension, hyperlipidaemia, diabetes mellitus, infections and malignancies. Chronic antibody mediated rejection and chronic allograft dysfunction still remain the major problems, often leading to graft loss and shortened long term graft survival. Immunosuppressive agents are used for induction, maintenance and reversal of established rejection. The use of multidrug regimen tailored to the immunological risk of patient and adverse effect profile of the drug provides the optimum outcomes. This review focuses on the evolution of immunosuppression agents used in RT over last six decades and highlights the newer agents under investigation. Neha Sharma "Immunoauppresive Drugs for Renal Transplantation" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-2 , February 2019, URL: https://www.ijtsrd.com/papers/ijtsrd21413.pdf Paper URL: https://www.ijtsrd.com/other-scientific-research-area/other/21413/immunoauppresive-drugs-for-renal-transplantation/neha-sharma

139 views • 12 slides

Immunomodulators Market Size, Share, Growth and Forecast to 2025 | Grand View Research

Immunomodulators Market Analysis By Product (Immunosuppressant, Immunostimulants, Vaccines, Antibodies), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2018 - 2025

105 views • 8 slides

Global Organ Transplant Immunosuppressant Drugs Market to Decline at -5.0% CAGR till 2023 due to Demand and Supply Imbal

The global organ transplant immunosuppressant drugs market was valued at US$5.1 bn in 2014 and is expected to decline at a CAGR of - (5.0)% from 2015 to 2023, to reach an estimated value of US$3.2 bn in 2023

190 views • 7 slides

Global Immunosuppressive Drugs Market is expected to cross USD 1.39 Billion by 2025 at a CAGR of 4.63%

Global Immunosuppressive Drugs Market expected to register at CAGR of 4.63% during the forecast period of 2019 to 2025 at USD 10,282 million. Immunosuppressive Drugs are antirejection medicines that obstruct or prevent activity of the immune system. The growth of the global immunosuppressive drugs market is driven by various factors such as the rising incidence rate of autoimmune diseases and increasing cases of organ failures with the need for organ transplantation. However, the high costs of transplantation procedures and the side effects of the drugs are expected to curb the growth of the global immunosuppressive drugs market.

64 views • 6 slides

Best way to treat seborrheic dermatitis

146 views • 3 slides